What dose of ezetimibe (Zetia) should be given to a patient already on ezetimibe 10 mg daily with an LDL‑cholesterol of 221 mg/dL?

Ezetimibe Dosing for Inadequate LDL Control

The patient should continue ezetimibe 10 mg daily (the only FDA-approved dose) and add a PCSK9 inhibitor to achieve adequate LDL-cholesterol reduction, as the LDL-C of 221 mg/dL far exceeds guideline targets despite current therapy. 1

Why Not Increase Ezetimibe Dose?

The FDA-approved dose of ezetimibe is 10 mg once daily, and this is the only recommended dosing 1. While one small retrospective study showed that 20 mg daily provided additional 10% LDL-C reduction in patients on statins 2, this is:

• Not FDA-approved
• Based on limited evidence (27 patients)
• Insufficient to address an LDL-C of 221 mg/dL

Ezetimibe 10 mg typically reduces LDL-C by approximately 18-25% when added to statin therapy 1, 3. Even doubling the dose would not bring this patient to goal.

The Correct Approach: Add PCSK9 Inhibitor

Risk Stratification First

Determine if this patient has:

• Very high risk: Clinical ASCVD (prior MI, stroke, ACS, PAD, etc.) → Target LDL-C <55-70 mg/dL 4, 5
• High risk: Diabetes with organ damage, severe CKD, SCORE ≥10% → Target LDL-C <70 mg/dL 4

Treatment Algorithm

For patients with very high cardiovascular risk:

1. Confirm patient is on maximally tolerated statin therapy
2. Continue ezetimibe 10 mg daily 1
3. Add PCSK9 inhibitor (evolocumab or alirocumab) when LDL-C remains ≥100 mg/dL on statin plus ezetimibe 4, 5

The 2022 ACC Expert Consensus strongly supports this approach: When LDL-C remains ≥70 mg/dL (or non-HDL-C ≥100 mg/dL) on maximally tolerated statin-ezetimibe combination, adding a PCSK9 monoclonal antibody is reasonable 5.

Why PCSK9 Inhibitors?

• PCSK9 inhibitors reduce LDL-C by 50-60% on top of statin-ezetimibe therapy
• The 2019 ESC/EAS guidelines give this combination a Class I recommendation (Level A evidence) for secondary prevention in very high-risk patients 4
• The Canadian Cardiovascular Society 2021 guidelines specifically recommend PCSK9 inhibitors when LDL-C remains ≥100 mg/dL on statin plus ezetimibe 4

Common Pitfalls to Avoid

1. Don't use off-label ezetimibe dosing when evidence-based alternatives exist
2. Don't assume the patient is on maximally tolerated statin - verify statin dose and intensity first
3. Don't delay PCSK9 inhibitor initiation in very high-risk patients with LDL-C >200 mg/dL - the absolute benefit is substantial
4. Consider referral to a lipid specialist for patients with baseline LDL-C ≥190 mg/dL who don't achieve adequate reduction 5

Alternative Consideration: Bempedoic Acid

If PCSK9 inhibitors are not accessible due to cost or insurance barriers, bempedoic acid may be added as a third-line agent, though it provides more modest LDL-C reduction (15-25%) 5. However, at an LDL-C of 221 mg/dL, this patient likely needs the more potent reduction offered by PCSK9 inhibitors.